ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/skin
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Melanoma and skin / Skin
24
trial(s) found.
NCT07651618
Advanced
Phase 2
Not yet recruiting
PERTIL-01
: A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma
Aldesleukin
Cyclophosphamide
Fludarabine
IL-2 variant
alkylating agent
antimetabolite
cancer therapy
cancer therapy,IL-2-targeting
cytokine therapy
cytokine therapy,IL-2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,IL-2-targeting
Melanoma
Skin cancer
WA
6000 - Perth - Royal Perth Hospital
NCT07341737
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours (
SL-28-FIH
)
allogeneic cell therapy,unspecified mechanism
Bladder cancer
Breast cancer
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Hepatocellular carcinoma
Kidney cancer
Lung adenocarcinoma
Lung cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06999980
Curative
Phase 2
Recruiting
A Phase II, Multicentre, Parallel Group, Open Label, Randomised Clinical Trial of Neoadjuvant Nivolumab and Ipilimumab Combined With Relatlimab for Patients With Resectable Advanced Melanoma Identified as Poor Responders to Immunotherapy (
Neo-IRENIE
)
anti-CTLA4 monoclonal antibody
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Cutaneous melanoma
Mucosal melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
NCT06926075
Advanced
Phase 1 / Phase 2
Recruiting
An Adaptive Phase I/II Study of KESONOTIDE™, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours (
ADVICE
)
hGIIA-vimentin inhibitor
Breast cancer
Glioblastoma
Lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Private Hospital
2228 - Miranda - Southside Cancer Care Centre
NCT06330064
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) (
DS7300-203
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Cutaneous melanoma
Endometrial cancer
Gastrooesophageal adenicarcoma
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
NOT Sarcoma
Ovarian cancer
Pancreatic adenocarcinoma
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06305962
Radonc
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours (
177Lu-RAD204.2023.0001
)
radioconjugate,PD-L1-targeting
Cutaneous melanoma
Endometrial cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06288191
Curative
Phase 2
Recruiting
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II To IV (M0) Resectable Cutaneous Squamous Cell Carcinoma (
MIA2023-490
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
NCT06151236
Curative
Phase 2
Recruiting
A Phase 2, Open Label, Single Arm Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage I To III Resectable Merkel Cell Carcinoma (
MIA2023-489
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Merkel cell carcinoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
NCT06022029
Haem
Phase 1
Recruiting
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (
ON-5001
)
STING agonist
anti-PD-1 monoclonal antibody
Bladder cancer
Cancer
Carcinoma
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck squamous cell carcinoma
Lymphoma
Mantle cell lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Cancer Care Wollongong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05267626
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (
CP-AU-007-01
)
anti-IL-2 monoclonal antibody
Cancer
Cutaneous melanoma
Non-small cell lung cancer
Solid tumour
NSW
2228 - Miranda - Southside Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT05025813
Curative
Phase 2
Recruiting
A Phase 2 Study of De-escalation in Resectable, Locally Advanced Cutaneous Squamous Cell Carcinoma With the Use of Neoadjuvant Pembrolizumab -
DESQUAMATE
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04429542
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors (
BCA101X1101
)
bifunctional EGFR/TGF-beta fusion protein
Anal squamous cell carcinoma
Carcinoma
Colorectal cancer
Cutaneous squamous cell carcinoma
Epithelial Ovarian Cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Pancreatic cancer
Squamous cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT03947385
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (
IDE196-001
)
PKC inhibitor
Colorectal cancer
Cutaneous melanoma
Solid tumour
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12626000435381
Advanced
Not Applicable
Recruiting
A Clinical Trial to Determine Safety and Tolerability of Targeted Osmotic Lysis in the Treatment of Well-Differentiated Cutaneous Squamous Cell Carcinoma. (
TOL-in-CSCC
)
Cutaneous squamous cell carcinoma
NSW
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
ACTRN12626000394347
Advanced
Phase 2
Not yet recruiting
A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients with Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma (
PERTIL-01
)
Aldesleukin
IL-2 variant
cancer therapy
cancer therapy,IL-2-targeting
cytokine therapy
cytokine therapy,IL-2-targeting
immuno-oncology therapy,IL-2-targeting
Melanoma
Skin cancer
ACTRN12625001151426
Curative
Not Applicable
Recruiting
Feasibility of delivering High Dose Palliative Radiotherapy in patients with Metastatic malignancy (
HD-PRiMe
)
radiotherapy
Bladder cancer
Cancer
Colorectal cancer
Cutaneous squamous cell carcinoma
Head and neck cancer
Non-small cell lung cancer
Oesophageal cancer
Pancreatic cancer
Skin cancer
Triple-negative breast cancer
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12625000197437
Advanced
Phase 2
Not yet recruiting
A single arm, phase II trial of Cemiplimab in Head and Neck Cutaneous Squamous Cell Carcinoma with Large Nerve Perineural Spread (
NIL-Known
)
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
Skin cancer
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12624000917538
Advanced
Phase 2
Not yet recruiting
Efficacy and safety of cetuximab and prochlorperazine combined for solid organ transplant patients with advanced Cutaneous Squamous Cell Carcinoma:
CetPro
study
anti-EGFR monoclonal antibody
antihistamine
Skin cancer
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12624000911594
Advanced
Phase 3
Not yet recruiting
CICAFU
Trial: Randomised, controlled trial of CICAPLAST Baume B5+ versus standard of care on tolerability and observance of topical 5% 5-fluorouracil in Patients diagnosed with Actinic Keratoses (AK)
fluoropyrimidine
Skin cancer
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12619001298101
Advanced
Phase 2
Not yet recruiting
A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas (
ASN-002-IL
)
SYK/JAK inhibitor
Cutaneous basal cell carcinoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
ACTRN12618001351202
Curative
Not Applicable
Not yet recruiting
A prospective case series evaluating neo-adjuvant use of Vismodegib in patients with periocular basal cell carcinoma to evaluate reduction in clinical and surgical tumour margins
SMO inhibitor,first generation
Cancer
Cutaneous basal cell carcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07288203
Advanced
Phase 2
Active not recruiting
A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Melanoma (
IOV-MEL-202
)
autologous tumor-infiltrating lymphocytes therapy
Melanoma
Skin cancer
QLD
4120 - Greenslopes - Greenslopes Private Hospital
NCT05642949
Advanced
Phase 1 / Phase 2
Unknown
Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors (
MHB036C-CP001EN
)
anti-Trop2 antibody-drug conjugate
Breast cancer
Endometrial cancer
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal squamous cell carcinoma
Ovarian cancer
Pancreatic adenocarcinoma
Prostate cancer
Small-cell lung cancer
Solid tumour
Sweat gland carcinoma
Urothelial carcinoma
VIC
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (15)
Not yet recruiting (7)
Active not recruiting (1)
Unknown (1)
Recruitment Country and State
NSW (13)
QLD (13)
SA (6)
WA (4)
VIC (3)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (7)
Phase 2 (10)
Phase 3 (1)
Trial Type
Advanced (16)
Curative (6)
Radonc (1)
Haem (1)
Cancer Therapy Class
PD-1/PD-L1
42%
PD-1
38%
IL-2
17%
LAG3
13%
PD-L1
8%
CTLA4
4%
hGIIA-vimentin
4%
B7H3
4%
STING
4%
ALK
4%
MEK
4%
MET
4%
PKC
4%
ROS1
4%
EGFR
4%
JAK
4%
SYK
4%
SMO
4%
Trop2
4%
Facility
4102 - Woolloongabba - Princess Alexandra Hospital (7)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (4)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
2228 - Miranda - Southside Cancer Care Centre (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4120 - Greenslopes - Greenslopes Private Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
6000 - Perth - Royal Perth Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2217 - Kogarah - St George Private Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2500 - Wollongong - Wollongong Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
5000 - Adelaide - Cancer Research SA (1)
6150 - Murdoch - GenesisCare Murdoch (1)
2500 - Wollongong - Cancer Care Wollongong (1)
4215 - Southport - Tasman Oncology (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2109 - North Ryde - Macquarie University Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
Cancer Type
Cancer
Skin cancer
Solid tumour
Melanoma
Non-melanoma skin cancer
Breast cancer
Gastrointestinal cancer
Gynaecological cancer
Head and neck cancer
Lung cancer
Pancreatic cancer
Pancreatobiliary cancer
Respiratory tract cancer
Thoracic cancer
Upper gastrointestinal cancer
Urogenital cancer
Cutaneous squamous cell carcinoma
Colorectal cancer
Lower gastrointestinal cancer
Non-small cell lung cancer
Ovarian cancer
Cutaneous melanoma
Head and neck squamous cell carcinoma
Endometrial cancer
Bladder cancer
Gastroesophageal cancer
Oesophageal cancer
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Breast adenocarcinoma
Carcinoma
Triple-negative breast cancer
Gastric cancer
Male genital cancers
Prostate cancer
Cervical cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Cutaneous basal cell carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Kidney cancer
Non-squamous non-small-cell lung cancer
Mucosal melanoma
Urothelial carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Merkel cell carcinoma
Uveal melanoma
Epithelial Ovarian Cancer
Lung adenocarcinoma
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Colorectal adenocarcinoma
Gastrooesophageal adenicarcoma
B-cell lymphoma
B-cell malignancy
Diffuse large B-cell lymphoma
Follicular lymphoma
Haematological malignancy
High-grade B-cell lymphoma
Lymphoma
Mantle cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Acral lentiginous melanoma
Biomarker-defined solid tumour
Clear cell renal cell carcinoma
Endometrial carcinoma
Fallopian tube cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
MSI-H/dMMR solid tumour
Mesothelioma
Peritoneal cancer
Pleural mesothelioma
Primary peritoneal serous carcinoma
Squamous non-small-cell lung cancer
dMMR solid cancer
Anal cancer
Anal squamous cell carcinoma
Squamous cell carcinoma
Oesophageal squamous cell carcinoma
Sweat gland carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy